Sinopharm Group Co

Sinopharm Group Co Current Liabilities

The Current Liabilities of Sinopharm Group Co (1099.HK) as of Oct 22, 2026 is 280.33 B CNY. In the previous year, Current Liabilities was 362.14 B CNY — a change of -22.59% (lower).

Current Liabilities

280.33 BCNY

YoY

-22.59%

Last updated:

Current Liabilities of Sinopharm Group Co is 2025 280.33 B CNY. Current Liabilities of Sinopharm Group Co was 2024 362.14 B CNY. It decreases by -22.59% lower compared to the previous year.

The Sinopharm Group Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
234.70 B CNY
Jan 1, 2019
247.96 B CNY
Jan 1, 2020
269.68 B CNY
Jan 1, 2021
291.65 B CNY
Jan 1, 2022
333.87 B CNY
Jan 1, 2023
342.96 B CNY
Jan 1, 2024
362.14 B CNY
Jan 1, 2025
280.33 B CNY
The Sinopharm Group Co Current Liabilities history
YEARCurrent LiabilitiesYoY
280.33 BCNY-22.59%
362.14 BCNY+5.59%
342.96 BCNY+2.72%
333.87 BCNY+14.48%
291.65 BCNY+8.15%
269.68 BCNY+8.76%
247.96 BCNY+5.65%
234.70 BCNY+35.24%
173.54 BCNY+26.19%
137.53 BCNY-0.84%
138.69 BCNY+10.07%
126.00 BCNY+20.94%
104.18 BCNY+49.64%
69.62 BCNY+23.97%
56.16 BCNY+66.91%
33.65 BCNY+53.50%
21.92 BCNY+40.09%
15.65 BCNY+7.32%
14.58 BCNY+24.81%
11.68 BCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sinopharm Group Co Stock analysis

What does Sinopharm Group Co do? Sinopharm Group Co Ltd is one of the largest Chinese companies in the healthcare industry and was founded in 1998. With its headquarters in Beijing, it has been a significant player in the global healthcare sector for many years and operates in various business areas. The company's history dates back to the 1940s when the original company, China National Pharmaceutical Industry Corporation, was founded. It was later transformed into China National Pharmaceutical Group and eventually renamed Sinopharm Group. Sinopharm's business model is designed to promote healthcare in China while expanding internationally. The company's key business areas include pharmaceutical research and development, drug manufacturing, and the import and export of pharmaceutical products. Overall, Sinopharm Group operates in various sectors, including the production of biological drugs, diagnostic products, medical devices, and medical consumables. Additionally, the company is involved in providing healthcare services such as hospital management and health tourism. An important part of Sinopharm's business is the export of drugs and other medical products. The company has established a global presence and maintains businesses and collaborations with companies in Asia, Europe, North America, and Africa. Furthermore, Sinopharm Group has established several subsidiaries to focus on specialized markets and products better. On the product side, Sinopharm offers a wide range of medications, health products, and medical devices. Some of the most well-known products include anti-cancer drugs, diabetes medications, vaccines, and blood products. The company also invests in research and development of new drugs and is involved in numerous clinical trials. The success of Sinopharm is also based on its close collaboration with the Chinese government. The company works closely with local and national authorities to meet the demand for healthcare products and services in China. The Chinese government also supports the company and promotes its expansion into other countries. Overall, Sinopharm Group has become a significant player in the global healthcare industry in recent years. The company has a strong presence in China and a growing international presence. With a wide range of products and services and a strong focus on research and development, Sinopharm Group is well-positioned to continue growing and adapting to the demands of the healthcare sector. Sinopharm Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sinopharm Group Co stock

Current Liabilities of Sinopharm Group Co is 280.33 B CNY in 2025.

Current Liabilities of Sinopharm Group Co changed from 362.14 B CNY to 280.33 B CNY, representing a -22.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Sinopharm Group Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Sinopharm Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Sinopharm Group Co

All Key Metrics — Sinopharm Group Co